• +1-646-491-9876
    • +91-20-67278686

    Search

    Chondrosarcoma-Pipeline Review H1 2017

    Chondrosarcoma-Pipeline Review H1 2017

    • Report Code ID: RW0001834366
    • Category Pharmaceuticals
    • No. of Pages 165
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Chondrosarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Pipeline Review, H1 2017, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.

    Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

    Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Chondrosarcoma - Overview 6
    Chondrosarcoma - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 9
    Products under Development by Companies 10
    Products under Development by Universities/Institutes 11
    Chondrosarcoma - Therapeutics Assessment 12
    Assessment by Target 12
    Assessment by Mechanism of Action 14
    Assessment by Route of Administration 16
    Assessment by Molecule Type 18
    Chondrosarcoma - Companies Involved in Therapeutics Development 20
    Agios Pharmaceuticals Inc 20
    Celgene Corp 20
    CytRx Corp 21
    Daiichi Sankyo Company Ltd 21
    EpiZyme Inc 22
    Horizon Pharma Plc 22
    Karyopharm Therapeutics Inc 23
    Merck & Co Inc 23
    Novartis AG 24
    Pfizer Inc 24
    Chondrosarcoma - Drug Profiles 25
    aldoxorubicin hydrochloride - Drug Profile 25
    Product Description 25
    Mechanism Of Action 25
    R&D Progress 25
    axitinib - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    DS-1001 - Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    enasidenib mesylate - Drug Profile 49
    Product Description 49
    Mechanism Of Action 49
    R&D Progress 49
    galarmin - Drug Profile 55
    Product Description 55
    Mechanism Of Action 55
    R&D Progress 55
    interferon gamma-1b - Drug Profile 56
    Product Description 56
    Mechanism Of Action 56
    R&D Progress 56
    ivosidenib - Drug Profile 61
    Product Description 61
    Mechanism Of Action 61
    R&D Progress 61
    ligerin - Drug Profile 67
    Product Description 67
    Mechanism Of Action 67
    R&D Progress 67
    pazopanib hydrochloride - Drug Profile 68
    Product Description 68
    Mechanism Of Action 68
    R&D Progress 68
    pembrolizumab - Drug Profile 76
    R&D Progress 77
    selinexor - Drug Profile 128
    Product Description 128
    Mechanism Of Action 128
    R&D Progress 128
    sirolimus - Drug Profile 149
    Product Description 149
    Mechanism Of Action 149
    R&D Progress 149
    tazemetostat - Drug Profile 151
    Product Description 151
    Mechanism Of Action 151
    R&D Progress 151
    Chondrosarcoma - Dormant Projects 160
    Chondrosarcoma - Discontinued Products 161
    Chondrosarcoma - Product Development Milestones 162
    Featured News & Press Releases 162
    Nov 18, 2016: Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma 162
    Appendix 164
    Methodology 164
    Coverage 164
    Secondary Research 164
    Primary Research 164
    Expert Panel Validation 164
    Contact Us 164
    Disclaimer 165

    List of Tables

    Number of Products under Development for Chondrosarcoma, H1 2017 7
    Number of Products under Development by Companies, H1 2017 8
    Number of Products under Development by Universities/Institutes, H1 2017 9
    Products under Development by Companies, H1 2017 10
    Products under Development by Universities/Institutes, H1 2017 11
    Number of Products by Stage and Target, H1 2017 13
    Number of Products by Stage and Mechanism of Action, H1 2017 15
    Number of Products by Stage and Route of Administration, H1 2017 17
    Number of Products by Stage and Molecule Type, H1 2017 19
    Chondrosarcoma - Pipeline by Agios Pharmaceuticals Inc, H1 2017 20
    Chondrosarcoma - Pipeline by Celgene Corp, H1 2017 20
    Chondrosarcoma - Pipeline by CytRx Corp, H1 2017 21
    Chondrosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 21
    Chondrosarcoma - Pipeline by EpiZyme Inc, H1 2017 22
    Chondrosarcoma - Pipeline by Horizon Pharma Plc, H1 2017 22
    Chondrosarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 23
    Chondrosarcoma - Pipeline by Merck & Co Inc, H1 2017 23
    Chondrosarcoma - Pipeline by Novartis AG, H1 2017 24
    Chondrosarcoma - Pipeline by Pfizer Inc, H1 2017 24
    Chondrosarcoma - Dormant Projects, H1 2017 160
    Chondrosarcoma - Discontinued Products, H1 2017 161

    List of Figures

    Number of Products under Development for Chondrosarcoma, H1 2017 7
    Number of Products under Development by Companies, H1 2017 8
    Number of Products by Top 10 Targets, H1 2017 12
    Number of Products by Stage and Top 10 Targets, H1 2017 12
    Number of Products by Top 10 Mechanism of Actions, H1 2017 14
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 14
    Number of Products by Routes of Administration, H1 2017 16
    Number of Products by Stage and Routes of Administration, H1 2017 16
    Number of Products by Molecule Types, H1 2017 18
    Number of Products by Stage and Molecule Types, H1 2017 18
    Agios Pharmaceuticals Inc 20
    Celgene Corp 20
    CytRx Corp 21
    Daiichi Sankyo Company Ltd 21
    EpiZyme Inc 22
    Horizon Pharma Plc 22
    Karyopharm Therapeutics Inc 23
    Merck & Co Inc 23
    Novartis AG 24

    Request for Sample

    Report Url https://www.reportsweb.com//chondrosarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//chondrosarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//chondrosarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments